Article
Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples.
The Prostate - 1 Apr 2022
Stover Elizabeth H, Oh Coyin, Keskula Paula, Choudhury Atish D, Tseng Yuen-Yi, Adalsteinsson Viktor A, Lohr Jens G, Thorner Aaron R, Ducar Matthew, Kryukov Gregory V, Ha Gavin, Rosenberg Mara, Freeman Samuel S, Zhang Zhenwei, Wu Xiaoyun, Van Allen Eliezer M, Takeda David Y, Loda Massimo, Wu Chin-Lee, Taplin Mary-Ellen, Garraway Levi A, Boehm Jesse S, Huang Franklin W
Abstract excerpt
BACKGROUND: Primary and metastatic prostate cancers have low mutation rates and recurrent alterations in a small set of genes, enabling targeted sequencing of prostate cancer-associated genes as an efficient approach to characterizing patient samples (compared to whole-exome and whole-genome sequencing). For example, targeted sequencing provides a flexible, rapid, and cost-effective method for genomic assessment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.